Weber Franziska, Reese Kim-Lea, Pantel Klaus, Smit Daniel J
Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
European Liquid Biopsy Society (ELBS), Martinistraße 52, 20246, Hamburg, Germany.
J Exp Clin Cancer Res. 2025 Apr 21;44(1):127. doi: 10.1186/s13046-025-03387-7.
Cancer-associated fibroblasts (CAFs) are tissue residing cells within the tumor microenvironment (TME). Stromal CAFs have been shown to be associated with poor prognosis and tumor progression in several solid tumor entities. Although the molecular mechanisms are not fully understood yet, a critical role within the TME through direct interaction with the tumor cells as well as other cells has been proposed. While most studies on CAFs focus on stromal CAFs, recent reports highlight the possibility of detecting circulating CAFs (cCAFs) in the blood. In contrast to invasive tissue biopsies for stromal CAF characterization, liquid biopsy allows a minimally invasive isolation of cCAFs. Furthermore, liquid biopsy methods could enable continuous monitoring of cCAFs in cancer patients and therefore may present a novel biomarker for solid tumors. In this work, we present an overview of cCAF studies currently available and summarize the liquid biopsy techniques for cCAF isolation and detection. Moreover, the future research directions in the emerging field are highlighted and the potential applications of cCAFs as novel biomarkers for solid tumor patients discussed.
癌症相关成纤维细胞(CAFs)是肿瘤微环境(TME)中的组织驻留细胞。在几种实体瘤中,基质CAFs已被证明与预后不良和肿瘤进展相关。尽管其分子机制尚未完全明确,但已有研究提出,CAFs通过与肿瘤细胞及其他细胞直接相互作用,在TME中发挥关键作用。虽然大多数关于CAFs的研究集中在基质CAFs,但最近的报告强调了在血液中检测循环CAFs(cCAFs)的可能性。与用于基质CAF表征的侵入性组织活检不同,液体活检能够以微创方式分离cCAFs。此外,液体活检方法可实现对癌症患者cCAFs的持续监测,因此可能成为实体瘤的一种新型生物标志物。在本文中,我们概述了目前可用的cCAF研究,并总结了用于cCAF分离和检测的液体活检技术。此外,还强调了这一新兴领域未来的研究方向,并讨论了cCAFs作为实体瘤患者新型生物标志物的潜在应用。